TWI748938B - 具抗腫瘤活性之化合物 - Google Patents

具抗腫瘤活性之化合物 Download PDF

Info

Publication number
TWI748938B
TWI748938B TW105103940A TW105103940A TWI748938B TW I748938 B TWI748938 B TW I748938B TW 105103940 A TW105103940 A TW 105103940A TW 105103940 A TW105103940 A TW 105103940A TW I748938 B TWI748938 B TW I748938B
Authority
TW
Taiwan
Prior art keywords
phenyl
methyl
ethoxymethyl
azol
amine
Prior art date
Application number
TW105103940A
Other languages
English (en)
Chinese (zh)
Other versions
TW201636345A (zh
Inventor
艾倫 穆西
安德拉 班傑漢
狄迪爾 派茲
法蘭克 珊卓尼利
傑森 馬汀
威利 畢考
伊曼紐 雀凡尼恩
Original Assignee
法商Ａｂ科學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商Ａｂ科學公司 filed Critical 法商Ａｂ科學公司
Publication of TW201636345A publication Critical patent/TW201636345A/zh
Application granted granted Critical
Publication of TWI748938B publication Critical patent/TWI748938B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW105103940A 2015-02-05 2016-02-05 具抗腫瘤活性之化合物 TWI748938B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15154028.3A EP3053920B1 (en) 2015-02-05 2015-02-05 Compounds with anti-tumoral activity
EP15154028.3 2015-02-05

Publications (2)

Publication Number Publication Date
TW201636345A TW201636345A (zh) 2016-10-16
TWI748938B true TWI748938B (zh) 2021-12-11

Family

ID=52450012

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105103940A TWI748938B (zh) 2015-02-05 2016-02-05 具抗腫瘤活性之化合物

Country Status (24)

Country Link
US (1) US10570122B2 (enExample)
EP (2) EP3053920B1 (enExample)
JP (1) JP6713000B2 (enExample)
KR (1) KR102544132B1 (enExample)
CN (1) CN107531685B (enExample)
AR (1) AR103629A1 (enExample)
AU (1) AU2016214283B2 (enExample)
BR (1) BR112017016883B1 (enExample)
CA (1) CA2975644C (enExample)
CY (1) CY1124948T1 (enExample)
DK (1) DK3253749T3 (enExample)
ES (2) ES2796276T3 (enExample)
HR (1) HRP20220114T1 (enExample)
HU (1) HUE059063T2 (enExample)
IL (1) IL253779A0 (enExample)
LT (1) LT3253749T (enExample)
MX (1) MX377742B (enExample)
PL (1) PL3253749T3 (enExample)
PT (1) PT3253749T (enExample)
RS (1) RS62901B1 (enExample)
RU (1) RU2758259C2 (enExample)
TW (1) TWI748938B (enExample)
WO (1) WO2016124747A1 (enExample)
ZA (1) ZA201705537B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN109467531A (zh) * 2017-09-08 2019-03-15 沈阳科创化学品有限公司 一种取代吡啶二羧酸衍生物的制备方法
CN112225733B (zh) * 2020-11-25 2022-12-09 湖南科技大学 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用
US12502854B2 (en) 2022-09-27 2025-12-23 Illinois Tool Works Inc. Tire repair system
AU2024225818A1 (en) * 2023-02-24 2025-09-11 Ab Science Compounds for treating myeloid diseases with chromosomal abnormalities
CN117720459A (zh) * 2023-12-26 2024-03-19 江苏希迪制药有限公司 一种阿贝西利中间体5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺制备工艺

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US810665A (en) * 1905-10-10 1906-01-23 Joseph Mlada Mold for butter.
US1346834A (en) * 1918-08-17 1920-07-20 Charles E Mcmanus Resilient rod
US3740420A (en) 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
US3743727A (en) 1970-11-16 1973-07-03 Crown Zellerbach Corp Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
CA1163561A (en) 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4411893A (en) 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
CA1236029A (en) 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6448272B1 (en) * 1998-12-07 2002-09-10 Smithkline Beecham Corporation Myt1 kinase inhibitors
JP4216947B2 (ja) * 1999-05-18 2009-01-28 三井化学株式会社 アミン化合物
MXPA05001277A (es) * 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
ATE465731T1 (de) * 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
CA2578122A1 (en) * 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
AU2006244203B2 (en) * 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
JP5214096B2 (ja) * 2005-06-17 2013-06-19 富士フイルムファインケミカルズ株式会社 新規なビピリジン誘導体
EP1904065A2 (en) * 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
AU2006290814B2 (en) * 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
GB0524436D0 (en) * 2005-11-30 2006-01-11 Novartis Ag Organic compounds
PT2402319T (pt) * 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
FR2901273B1 (fr) * 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
BRPI0806811A2 (pt) * 2007-01-23 2011-09-13 Palau Pharma Sa derivados de purina
KR20090113382A (ko) * 2007-02-22 2009-10-30 아이알엠 엘엘씨 Ｇ 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2310384B1 (en) * 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2012180281A (ja) * 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
WO2011006903A1 (en) * 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
EP2499282B1 (en) * 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
GB201012105D0 (en) * 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
EP2616443A1 (en) * 2010-09-14 2013-07-24 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
WO2012068210A1 (en) * 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012162461A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012166463A2 (en) * 2011-05-27 2012-12-06 Neosome Life Sciences, LLC Aminooxazole inhibitors of cyclin dependent kinases
ES2573831T3 (es) * 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
KR101896035B1 (ko) * 2011-08-23 2018-09-07 덕산네오룩스 주식회사 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말
CN103436048B (zh) * 2013-08-08 2014-12-03 陕西师范大学 硫脲供体双桥链有机染料及其应用
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
MX2016012460A (es) * 2014-03-24 2017-05-04 Ab Science Derivados de oxazol sustituidos por diazaespiroalcanona como inhibidores de torosina quinasa de bazo.
EP3144307A1 (en) * 2015-09-18 2017-03-22 AB Science Novel oxazole derivatives that inhibit syk

Also Published As

Publication number Publication date
PT3253749T (pt) 2022-02-03
PL3253749T3 (pl) 2022-03-07
JP2018504415A (ja) 2018-02-15
HRP20220114T1 (hr) 2022-04-15
CN107531685A (zh) 2018-01-02
LT3253749T (lt) 2022-02-25
RU2017127484A3 (enExample) 2019-08-14
DK3253749T3 (da) 2022-02-28
ES2905412T3 (es) 2022-04-08
CA2975644A1 (en) 2016-08-11
US10570122B2 (en) 2020-02-25
CN107531685B (zh) 2021-04-23
EP3053920A1 (en) 2016-08-10
EP3253749B1 (en) 2021-12-08
MX2017010157A (es) 2017-12-18
WO2016124747A1 (en) 2016-08-11
AU2016214283B2 (en) 2020-07-16
US20180079747A1 (en) 2018-03-22
CY1124948T1 (el) 2023-01-05
IL253779A0 (en) 2017-09-28
MX377742B (es) 2025-03-11
ES2796276T3 (es) 2020-11-26
RS62901B1 (sr) 2022-03-31
KR102544132B1 (ko) 2023-06-15
BR112017016883A2 (pt) 2018-03-27
AR103629A1 (es) 2017-05-24
HUE059063T2 (hu) 2022-10-28
KR20170117407A (ko) 2017-10-23
TW201636345A (zh) 2016-10-16
EP3053920B1 (en) 2020-04-08
ZA201705537B (en) 2020-11-25
RU2017127484A (ru) 2019-03-05
JP6713000B2 (ja) 2020-06-24
EP3253749A1 (en) 2017-12-13
BR112017016883B1 (pt) 2023-03-07
AU2016214283A1 (en) 2017-08-10
HK1243700A1 (zh) 2018-07-20
CA2975644C (en) 2025-05-06
RU2758259C2 (ru) 2021-10-27

Similar Documents

Publication Publication Date Title
JP6355648B2 (ja) Ｗｎｔシグナル伝達経路の３−（ベンゾイミダゾール−２−イル）−インダゾール阻害剤およびそれらの治療的使用
CN107531685B (zh) 具有抗肿瘤活性的化合物
WO2020102686A1 (en) Erk inhibitors and uses thereof
JP5944503B2 (ja) 選択的プロテインキナーゼ阻害剤
ES2947089T3 (es) Compuestos como antagonistas del receptor histamínico 3 neuronal y usos de los mismos
CN105073738A (zh) 作为钠通道调节剂的喹啉及喹唑啉酰胺类
CN104606194A (zh) Pde4的双环杂芳基抑制剂
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
CA2973773C (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
CA3104521A1 (en) Pikfyve inhibitors
JP2018504415A5 (enExample)
JP2007510667A (ja) 癌の治療法
JP2025535816A (ja) 縮合複素環化合物及びその使用
TW202525792A (zh) 經取代之側氧異吲哚啉基哌啶－２，６－二酮化合物
US20180202388A1 (en) Piston for an internal combustion engine and method for producing the piston for an internal combustion engine
CA2943316A1 (en) Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
US10736884B2 (en) Compositions and methods of Rit1 inhibition
JP2014515026A (ja) アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法
TWI403509B (zh) 一種用以治療癌症之藥學組合物
HK1225031A1 (en) Compounds with anti-tumoral activity
HK1225031A (en) Compounds with anti-tumoral activity
HK1243700B (en) Compounds with anti-tumoral activity

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees